 |
|
|
|
|
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Nativis Inc.
| | | | | Phone: | (206) 708-2288 | | Year Established: | 2002 | | Main Contact: | Michael Mischke-ReedsMischke-Reeds, Senior VP, Business Development | | | | Other Contacts: | Michael K. Matysik, MBA, CFO
Donna Morgan Murray, PhD, CRO
Deborah Sheffield, MSc, Head of Quality Systems, Clinical and Regulatory Affairs
Xavier A. Figueroa, Ph.D., Director, Pre-clinical Development
Steven E. Pope, Senior VP, General Counsel
Kenneth Ferguson, Ph.D., CSO
Eric Peterson, Director of Development & Manufacturing
Chris E. Rivera, President & CEO
| | | | Company Description | | Nativis, formerly WavBank, is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain. | |
|
|
|
|
|
|
|
